Browse Government Accountability Office (GAO) reports by subject "Pharmaceutical industry"- LegiStorm

Weekly Updates

LegiStorm is constantly adding new information on the people, places and reports in our database. In the past week, LegiStorm added:

1865 new people
34 new organizations
622 new photos
1247 job history records for people in our database
518 education records for people in our database
2209 contact addresses, emails and URLs (LinkedIn, Facebook, etc.)
198 new policy reports
12 new trips to our privately funded travel database
921 new personal financial disclosures
27459 new press releases
30 new town halls

Caught Our Eye Rss

GOP is center stage and talk of the town halls

by Sean McGlinn on 12/20/2024
Congressional trips highlight coastal charm

by Sean McGlinn on 12/18/2024
House female staffers poised to widen historic wage gap

by Caleb Mynatt on 12/16/2024
Landing on the Hill after a mission with NASA

by Sean McGlinn on 12/13/2024
Incoming House Republican recruits new comms director

by Sean McGlinn on 12/11/2024

» More from Caught Our Eye

Follow @LegiStorm

LegiStorm adds House Q2 salaries and expenses

2024-09-05
Latest Senate salary and expense records published

2024-06-10
LegiStorm adds House Q1 salaries and expenses

2024-06-05
LegiStorm adds Q4 salary analytics and turnover data

2024-03-14

» More from our DevBlog

Spartz to boycott committees, GOP caucus

by Indiana Capital Chronicle on 12/17/2024
New jobs that caught our eye

by Axios on 12/06/2024
LegiStorm rebuffs Wohl and Burkman’s AI lobbying software

by Politico on 11/26/2024

GAO Reports by subject "Pharmaceutical industry"

Full-text search of 52,071 reports from the Government Accountability Office

Full-text search

Report type

Period From To

Title

Report or Bill No.

Reset

Search Results:

Date	Report No.	Title
Date Oct. 4, 2011	Report No. GAO-12-104T	Title Medicare Part D: Instances of Questionable Access to Prescription Drugs United States Government Accountability Office GAO For Release on Delivery Expected at 10:30 a.m. EDT Tuesday, October 4, 2011 Testimony Before the Subcommittee on Federal Financial Management, Government Information, Federal Services, and International Security, Committee on Homeland Security and Governmental Affairs, U.S. Senate MEDICARE PART D Instances of Questionable Access to Prescription Dr...
Date Sept. 23, 2011	Report No. GAO-11-836	Title Drug Pricing: Manufacturer Discounts in the 340B Program Offer Benefits, but Federal Oversight Needs Improvement United States Government Accountability Office GAO September 2011 Report to Congressional Committees DRUG PRICING Manufacturer Discounts in the 340B Program Offer Benefits, but Federal Oversight Needs Improvement GAO-11-836 September 2011 DRUG PRICING Manufacturer Discounts in the 340B Program Offer Benefits, but Federal Oversight Needs Improvement Highlights of GAO-11-836, a report to congression...
Date Sept. 14, 2011	Report No. GAO-11-936T	Title Drug Safety: FDA Faces Challenges Overseeing the Foreign Drug Manufacturing Supply Chain United States Government Accountability Office GAO For Release on Delivery Expected at 10:00 a.m. EDT Wednesday, September 14, 2011 Testimony Before the Committee on Health, Education, Labor, and Pensions, U.S. Senate DRUG SAFETY FDA Faces Challenges Overseeing the Foreign Drug Manufacturing Supply Chain Statement of Marcia Crosse Director, Health Care GAO-11-936T September 14, 2011 DRUG SAFETY FD...
Date Sept. 6, 2011	Report No. GAO-11-699	Title Medicare Part D: Instances of Questionable Access to Prescription Drugs United States Government Accountability Office GAO September 2011 Report to Congressional Requesters MEDICARE PART D Instances of Questionable Access to Prescription Drugs GAO-11-699 September 2011 MEDICARE PART D Instances of Questionable Access to Prescription Drugs Highlights of GAO-11-699, a report to congressional requesters Why GAO Did This Study In 2009, GAO reported on doctor shopping in M...
Date Aug. 26, 2011	Report No. GAO-11-744	Title Prescription Drug Control: DEA Has Enhanced Efforts to Combat Diversion, but Could Better Assess and Report Program Results United States Government Accountability Office GAO August 2011 Report to Congressional Requesters PRESCRIPTION DRUG CONTROL DEA Has Enhanced Efforts to Combat Diversion, but Could Better Assess and Report Program Results GAO-11-744 August 2011 PRESCRIPTION DRUG CONTROL DEA Has Enhanced Efforts to Combat Diversion, but Could Better Assess and Report Program Results Highlights of GAO-11-744, a repor...
Date June 27, 2011	Report No. GAO-11-435	Title Influenza Vaccine: Federal Investments in Alternative Technologies and Challenges to Development and Licensure United States Government Accountability Office GAO June 2011 Report to Congressional Requesters INFLUENZA VACCINE Federal Investments in Alternative Technologies and Challenges to Development and Licensure GAO-11-435 June 2011 INFLUENZA VACCINE Accountability • Integrity • Reliability Federal Investments in Alternative Technologies and Challenges to Development and Licensure Highlights of GAO-...
Date June 1, 2011	Report No. GAO-11-406	Title Antibiotic Resistance: Data Gaps Will Remain Despite HHS Taking Steps to Improve Monitoring United States Government Accountability Office GAO June 2011 Report to the Committee on Agriculture, House of Representatives ANTIBIOTIC RESISTANCE Data Gaps Will Remain Despite HHS Taking Steps to Improve Monitoring GAO-11-406 June 2011 ANTIBIOTIC RESISTANCE Accountability • Integrity • Reliability Data Gaps Will Remain Despite HHS Taking Steps to Improve Monitoring Highlights of GAO-11-406, ...
Date March 23, 2011	Report No. GAO-11-365	Title End-Stage Renal Disease: CMS Should Assess Adequacy of Payment When Certain Oral Drugs Are Included and Ensure Availability of Quality Monitoring Data United States Government Accountability Office GAO March 2011 Report to Congressional Committees END-STAGE RENAL DISEASE CMS Should Assess Adequacy of Payment When Certain Oral Drugs Are Included and Ensure Availability of Quality Monitoring Data GAO-11-365 March 2011 END-STAGE RENAL DISEASE Accountability • Integrity • Reliability CMS Should Assess Adequacy of Payment When Certain Oral Drugs ...
Date Feb. 10, 2011	Report No. GAO-11-306R	Title Prescription Drugs: Trends in Usual and Customary Prices for Commonly Used Drugs United States Government Accountability Office Washington, DC 20548 February 10, 2011 Congressional Requesters Subject: Prescription Drugs: Trends in Usual and Customary Prices for Commonly Used Drugs Prescription drug spending in 2009 totaled approximately $250 billion, of which $78 billion— or about 31 percent—was spent by the federal government. 1 Prescription drug spending by the federal g...
Date Dec. 15, 2010	Report No. GAO-11-141R	Title Medicaid Outpatient Prescription Drugs: Estimated Changes to Federal Upper Limits Using the Formula under the Patient Protection and Affordable Care Act United States Government Accountability Office Washington, DC 20548 December 15, 2010 The Honorable Henry A. Waxman Chairman Committee on Energy and Commerce House of Representatives Subject: Medicaid Outpatient Prescription Drugs: Estimated Changes to Federal Upper Limits Using the Formula under the Patient Protection and Affordable Care Act Dear Mr. Chairman: Spending on prescription drugs in Me...
Date Sept. 30, 2010	Report No. GAO-10-961	Title Drug Safety: FDA Has Conducted More Foreign Inspections and Begun to Improve Its Information on Foreign Establishments, but More Progress Is Needed United States Government Accountability Office GAO September 2010 Report to the Committee on Oversight and Government Reform, House of Representatives DRUG SAFETY FDA Has Conducted More Foreign Inspections and Begun to Improve Its Information on Foreign Establishments, but More Progress Is Needed GAO-10-961 September 2010 DRUG SAFETY Accountability • Integrity • Reliability FDA Has Conducted M...
Date July 30, 2010	Report No. GAO-10-798	Title New Drug Approval: FDA's Consideration of Evidence from Certain Clinical Trials United States Government Accountability Office GAO July 2010 Report to Congressional Requesters NEW DRUG APPROVAL FDA’s Consideration of Evidence from Certain Clinical Trials GAO-10-798 July 2010 NEW DRUG APPROVAL Highlights Highlights of GAO-10-798, a report to congressional requesters Accountability Integrity Reliability FDA’s Consideration of Evidence from Certain Clinical Trials Why GAO Di...
Date June 7, 2010	Report No. GAO-10-426	Title Home Infusion Therapy: Differences between Medicare and Private Insurers' Coverage United States Government Accountability Office GAO June 2010 Report to Congressional Requesters HOME INFUSION THERAPY Differences between Medicare and Private Insurers’ Coverage GAO-10-426 June 2010 HOME INFUSION THERAPY Highlights Highlights of GAO-10-426, a report to congressional requesters Accountability Integrity Reliability Differences between Medicare and Private Insurers’ Coverage Why ...
Date March 17, 2010	Report No. GAO-10-529T	Title Medicare Part D: Spending, Beneficiary Out-of-Pocket Costs, and Efforts to Obtain Price Concessions for Certain High-Cost Drugs United States Government Accountability Office GAO For Release on Delivery Expected at 2:30 p.m. EDT Wednesday, March 17, 2010 Testimony Before the Special Committee on Aging, U.S. Senate MEDICARE PART D Spending, Beneficiary Outof-Pocket Costs, and Efforts to Obtain Price Concessions for Certain High-Cost Drugs Statement of John E. Dicken Director, Health Care GAO-10-529T March 17, 2010 MEDICARE ...
Date Jan. 29, 2010	Report No. GAO-10-242	Title Medicare Part D: Spending, Beneficiary Cost Sharing, and Cost-Containment Efforts for High-Cost Drugs Eligible for a Specialty Tier United States Government Accountability Office GAO January 2010 Report to the Chairman, Subcommittee on Health, Committee on Ways and Means, House of Representatives MEDICARE PART D Spending, Beneficiary Cost Sharing, and Cost-Containment Efforts for High-Cost Drugs Eligible for a Specialty Tier GAO-10-242 January 2010 MEDICARE PART D Highlights Highlights of GAO-10-242, a report to the Chairman, ...
Date Dec. 22, 2009	Report No. GAO-10-201	Title Brand-Name Prescription Drug Pricing: Lack of Therapeutically Equivalent Drugs and Limited Competition May Contribute to Extraordinary Price Increases United States Government Accountability Office GAO December 2009 Report to Congressional Requesters BRAND-NAME PRESCRIPTION DRUG PRICING Lack of Therapeutically Equivalent Drugs and Limited Competition May Contribute to Extraordinary Price Increases GAO-10-201 December 2009 BRAND-NAME PRESCRIPTION DRUG PRICING Highlights Highlights of GAO-10-201, a report to congressional requesters Accountability...
Date Nov. 30, 2009	Report No. GAO-10-118R	Title Medicaid Outpatient Prescription Drugs: Second Quarter 2008 Federal Upper Limits for Reimbursement Compared with Average Retail Pharmacy Acquisition Costs United States Government Accountability Office Washington, DC 20548 November 30, 2009 The Honorable Charles E. Grassley Ranking Member Committee on Finance United States Senate Subject: Medicaid Outpatient Prescription Drugs: Second Quarter 2008 Federal Upper Limits for Reimbursement Compared with Average Retail Pharmacy Acquisition Costs Dear Senator Grassley: Medicaid—the joint federal-state p...
Date Nov. 9, 2009	Report No. GAO-10-68	Title Drug Safety: FDA Has Begun Efforts to Enhance Postmarket Safety, but Additional Actions Are Needed United States Government Accountability Office GAO November 2009 Report to the Ranking Member, Committee on Finance, U.S. Senate DRUG SAFETY FDA Has Begun Efforts to Enhance Postmarket Safety, but Additional Actions Are Needed GAO-10-68 November 2009 DRUG SAFETY Highlights Highlights of GAO-10-68, a report to the Ranking Member, Committee on Finance, U.S. Senate Accountability Integrity Reliabilit...
Date Sept. 30, 2009	Report No. GAO-09-1004T	Title Medicaid: Fraud and Abuse Related to Controlled Substances Identified in Selected States United States Government Accountability Office GAO For Release on Delivery Expected at 3:00 p.m. EDT Wednesday, September 30, 2009 Testimony before the Subcommittee on Federal Financial Management, Government Information, Federal Services, and International Security, Committee on Homeland Security and Governmental Affairs, U.S. Senate MEDICAID Fraud and Abuse Related to Controlled Substances Ident...
Date Sept. 9, 2009	Report No. GAO-09-957	Title Medicaid: Fraud and Abuse Related to Controlled Substances Identified in Selected States United States Government Accountability Office GAO September 2009 Report to Congressional Requesters MEDICAID Fraud and Abuse Related to Controlled Substances Identified in Selected States GAO-09-957 September 2009 MEDICAID Highlights Highlights of GAO-09-957, a report to congressional requesters Accountability Integrity Reliability Fraud and Abuse Related to Controlled Substances Identified in Se...
Date June 24, 2009	Report No. GAO-09-819T	Title Prescription Drugs: Overview of Approaches to Control Prescription Drug Spending in Federal Programs United States Government Accountability Office GAO For Release on Delivery Expected at 2:00 p.m. EDT Wednesday, June 24, 2009 Testimony Before the Subcommittee on Federal Workforce, Postal Service, and the District of Columbia, Committee on Oversight and Government Reform, House of Representatives PRESCRIPTION DRUGS Overview of Approaches to Control Prescription Drug Spending in Federal Programs S...
Date March 26, 2009	Report No. GAO-09-341	Title Methadone-Associated Overdose Deaths: Factors Contributing to Increased Deaths and Efforts to Prevent Them United States Government Accountability Office GAO March 2009 Report to Congressional Requesters METHADONEASSOCIATED OVERDOSE DEATHS Factors Contributing to Increased Deaths and Efforts to Prevent Them GAO-09-341 March 2009 Highlights Highlights of GAO-09-341, a report to congressional requesters Accountability Integrity Reliability METHADONE-ASSOCIATED OVERDOSE DEATHS Factors Contributing to Incr...
Date Feb. 20, 2009	Report No. GAO-09-245	Title Nonprescription Drugs: Considerations Regarding a Behind-the-Counter Drug Class United States Government Accountability Office GAO February 2009 Report to Congressional Requesters NONPRESCRIPTION DRUGS Considerations Regarding a Behind-the-Counter Drug Class GAO-09-245 February 2009 NONPRESCRIPTION DRUGS Highlights Highlights of GAO-09-245, a report to congressional requesters Accountability Integrity Reliability Considerations Regarding a Behind-the-Counter Drug Class Why GA...
Date Dec. 12, 2008	Report No. GAO-09-4	Title Medicare Part D: Opportunities Exist for Improving Information Sent to Enrollees and Scheduling the Annual Election Period United States Government Accountability Office GAO December 2008 Report to the Chairman, Committee on Energy and Commerce, House of Representatives MEDICARE PART D Opportunities Exist for Improving Information Sent to Enrollees and Scheduling the Annual Election Period GAO-09-4 December 2008 MEDICARE PART D Highlights Highlights of GAO-09-4, a report to the Chairman, Committee on Energy and Commer...
Date Sept. 30, 2008	Report No. GAO-08-1074R	Title Medicare Part D Prescription Drug Coverage: Federal Oversight of Reported Price Concessions Data United States Government Accountability Office Washington, DC 20548 September 30, 2008 The Honorable Henry A. Waxman Chairman Committee on Oversight and Government Reform House of Representatives Subject: Medicare Part D Prescription Drug Coverage: Federal Oversight of Reported Price Concessions Data Dear Mr. Chairman: To help Medicare beneficiaries manage the rising cost of prescription drugs, Co...
Date Sept. 30, 2008	Report No. GAO-08-671	Title Influenza Pandemic: HHS Needs to Continue Its Actions and Finalize Guidance for Pharmaceutical Interventions United States Government Accountability Office GAO September 2008 Report to Congressional Requesters INFLUENZA PANDEMIC HHS Needs to Continue Its Actions and Finalize Guidance for Pharmaceutical Interventions GAO-08-671 September 2008 INFLUENZA PANDEMIC Highlights Highlights of GAO-08-671, a report to congressional requesters Accountability Integrity Reliability HHS Needs to Continue Its Actions a...
Date Aug. 7, 2008	Report No. GAO-08-751	Title Food and Drug Administration: Approval and Oversight of the Drug Mifeprex United States Government Accountability Office GAO August 2008 Report to Congressional Requesters FOOD AND DRUG ADMINISTRATION Approval and Oversight of the Drug Mifeprex GAO-08-751 August 2008 FOOD AND DRUG ADMINISTRATION Highlights Highlights of GAO-08-751, a report to congressional requesters Accountability Integrity Reliability Approval and Oversight of the Drug Mifeprex Why GAO Did This Study...
Date July 28, 2008	Report No. GAO-08-835	Title Prescription Drugs: FDA's Oversight of the Promotion of Drugs for Off-Label Uses United States Government Accountability Office GAO July 2008 Report to the Ranking Member, Committee on Finance, U.S. Senate PRESCRIPTION DRUGS FDA’s Oversight of the Promotion of Drugs for Off-Label Uses GAO-08-835 July 2008 PRESCRIPTION DRUGS Highlights Highlights of GAO-08-835, a report to the Ranking Member, Committee on Finance, U.S. Senate Accountability Integrity Reliability FDA’s Overs...
Date May 8, 2008	Report No. GAO-08-758T	Title Prescription Drugs: Trends in FDA's Oversight of Direct-to-Consumer Advertising United States Government Accountability Office GAO For Release on Delivery Expected at 10:00 a.m. EDT Thursday, May 8, 2008 Testimony Before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives PRESCRIPTION DRUGS Trends in FDA’s Oversight of Direct-to-Consumer Advertising Statement of Marcia Crosse Director, Health Care GAO-08-758T May 8, 2...
Date April 4, 2008	Report No. GAO-08-327	Title DOD Pharmacy Program: Continued Efforts Needed to Reduce Growth in Spending at Retail Pharmacies United States Government Accountability Office GAO April 2008 Report to Congressional Committees DOD PHARMACY PROGRAM Continued Efforts Needed to Reduce Growth in Spending at Retail Pharmacies GAO-08-327 April 2008 DOD PHARMACY PROGRAM Highlights Highlights of GAO-08-327, a report to congressional committees Accountability Integrity Reliability Continued Efforts Needed to Reduce Growth in Spending...
Date Oct. 31, 2007	Report No. GAO-08-27	Title Influenza Vaccine: Issues Related to Production, Distribution, and Public Health Messages United States Government Accountability Office GAO October 2007 Report to the Committee on Oversight and Government Reform, House of Representatives INFLUENZA VACCINE Issues Related to Production, Distribution, and Public Health Messages GAO-08-27 October 2007 INFLUENZA VACCINE Highlights Highlights of GAO-08-27, a report to the Committee on Oversight and Government Reform, House of Representative...
Date June 21, 2007	Report No. GAO-07-1022T	Title Medicare Part D: CMS's Process and Policy for Enrolling New Dual-Eligible Beneficiaries United States Government Accountability Office GAO For Release on Delivery Expected at 2:00 p.m. EDT Thursday, June 21, 2007 Testimony Before the Subcommittee on Health, Committee on Ways and Means, House of Representatives MEDICARE PART D CMS’s Process and Policy for Enrolling New DualEligible Beneficiaries Statement of Kathleen M. King Director, Health Care GAO-07-1022T June 21, 2007 MEDICARE ...
Date May 9, 2007	Report No. GAO-07-856T	Title Drug Safety: Further Actions Needed to Improve FDA's Postmarket Decision-making Process United States Government Accountability Office GAO For Release on Delivery Expected at 10:00 a.m. EDT May 9, 2007 Testimony Before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives DRUG SAFETY Further Actions Needed to Improve FDA’s Postmarket Decision-making Process Statement of Marcia Crosse Director, Health Care GAO-07-856T May 9, 2007 DRUG SAFETY Highligh...
Date May 8, 2007	Report No. GAO-07-824T	Title Medicare Part D: Enrolling New Dual-Eligible Beneficiaries in Prescription Drug Plans United States Government Accountability Office GAO For Release on Delivery Expected at 10:00 a.m. EDT Tuesday, May 8, 2007 Testimony Before the Committee on Finance, U.S. Senate MEDICARE PART D Enrolling New Dual-Eligible Beneficiaries in Prescription Drug Plans Statement of Kathleen M. King Director, Health Care GAO-07-824T May 8, 2007 MEDICARE PART D Highlights Highlights of GAO-07-824T, a testi...
Date May 4, 2007	Report No. GAO-07-272	Title Medicare Part D: Challenges in Enrolling New Dual-Eligible Beneficiaries United States Government Accountability Office GAO May 2007 Report to Congressional Requesters MEDICARE PART D Challenges in Enrolling New Dual-Eligible Beneficiaries GAO-07-272 May 2007 MEDICARE PART D Highlights Highlights of GAO-07-272, a report to congressional requesters Accountability Integrity Reliability Challenges in Enrolling New Dual-Eligible Beneficiaries Why GAO Did This Study Since J...
Date March 30, 2007	Report No. GAO-07-571R	Title Food and Drug Administration: Revenue Information on Certain Companies Participating in the Medical Device User Fee Program United States Government Accountability Office Washington, DC 20548 March 30, 2007 The Honorable Joe Barton Ranking Minority Member Committee on Energy and Commerce House of Representatives Subject: Food and Drug Administration: Revenue Information on Certain Companies Participating in the Medical Device User Fee Program Dear Mr. Barton: The Food and Drug Administration (FDA) is responsible for ap...
Date March 22, 2007	Report No. GAO-07-599T	Title Drug Safety: FDA Needs to Further Address Shortcomings in Its Postmarket Decision-making Process United States Government Accountability Office GAO For Release on Delivery Expected at 9:30 a.m. EDT March 22, 2007 Testimony Before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives DRUG SAFETY FDA Needs to Further Address Shortcomings in Its Postmarket Decisionmaking Process Statement of Marcia Crosse Director, Health Care GAO-07-599T Ma...
Date Feb. 9, 2007	Report No. GAO-07-481T	Title Prescription Drugs: Oversight of Drug Pricing in Federal Programs United States Government Accountability Office GAO For Release on Delivery Expected at 10:00 a.m. EST Friday, February 9, 2007 Testimony Before the Committee on Oversight and Government Reform, House of Representatives PRESCRIPTION DRUGS Oversight of Drug Pricing in Federal Programs Statement of John E. Dicken Director, Health Care GAO-07-481T February 9, 2007 PRESCRIPTION DRUGS Highlights Highlig...
Date Jan. 11, 2007	Report No. GAO-07-358T	Title Prescription Drugs: An Overview of Approaches to Negotiate Drug Prices Used by Other Countries and U.S. Private Payers and Federal Programs United States Government Accountability Office GAO For Release on Delivery Expected at 10:00 a.m. EST Thursday, January 11, 2007 Testimony Before the Committee on Finance, U.S. Senate PRESCRIPTION DRUGS An Overview of Approaches to Negotiate Drug Prices Used by Other Countries and U.S. Private Payers and Federal Programs Statement of John E. Dicken Director, Health Care GAO-07-358T January 11, 200...
Date Nov. 17, 2006	Report No. GAO-07-49	Title New Drug Development: Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts United States Government Accountability Office GAO November 2006 Report to Congressional Requesters NEW DRUG DEVELOPMENT Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts GAO-07-49 November 2006 NEW DRUG DEVELOPMENT Highlights Highlights of GAO-07-49, a report to congressional requesters Accountability Integrity Reliability Science, Busines...
Date Nov. 16, 2006	Report No. GAO-07-54	Title Prescription Drugs: Improvements Needed in FDA's Oversight of Direct-to-Consumer Advertising United States Government Accountability Office GAO November 2006 Report to Congressional Requesters PRESCRIPTION DRUGS Improvements Needed in FDA’s Oversight of Direct-to-Consumer Advertising GAO-07-54 November 2006 PRESCRIPTION DRUGS Highlights Highlights of GAO-07-54, a report to congressional requesters Accountability Integrity Reliability Improvements Needed in FDA’s Oversight of Direct-to...
Date July 13, 2006	Report No. GAO-06-971T	Title Medicare Part B Drugs: CMS Data Source for Setting Payments Is Practical but Concerns Remain United States Government Accountability Office GAO For Release on Delivery Expected at 1:00 p.m. EDT Thursday, July 13, 2006 Testimony Before the Subcommittee on Health, Committee on Ways and Means, House of Representatives MEDICARE PART B DRUGS CMS Data Source for Setting Payments Is Practical but Concerns Remain Statement of A. Bruce Steinwald Director, Health Care GAO-06-971T July 13, 2006 MEDI...
Date April 28, 2006	Report No. GAO-06-372	Title Medicare Hospital Pharmaceuticals: Survey Shows Price Variation and Highlights Data Collection Lessons and Outpatient Rate-Setting Challenges for CMS United States Government Accountability Office GAO April 2006 Report to Congressional Committees MEDICARE HOSPITAL PHARMACEUTICALS Survey Shows Price Variation and Highlights Data Collection Lessons and Outpatient Rate-Setting Challenges for CMS GAO-06-372 April 2006 Highlights Highlights of GAO-06-372, a report to congressional committees Accountability Integrity Reliability MEDICARE HOSPITAL PHA...
Date March 31, 2006	Report No. GAO-06-402	Title Drug Safety: Improvement Needed in FDA's Postmarket Decision-making and Oversight Process United States Government Accountability Office GAO March 2006 Report to Congressional Requesters DRUG SAFETY Improvement Needed in FDA’s Postmarket Decision-making and Oversight Process GAO-06-402 March 2006 DRUG SAFETY Highlights Highlights of GAO-06-402, a report to the Chairman, Committee on Finance, United States Senate and the Chairman, Committee on Energy and Commerce, House of Representat...
Date Dec. 13, 2005	Report No. GAO-06-175T	Title Prescription Drugs: Enhanced Efforts and Better Agency Coordination Needed to Address Illegal Importation United States Government Accountability Office GAO For Release on Delivery Expected at 1:00 p.m. EST Tuesday, December 13, 2005 Testimony Before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, U.S. House of Representatives PRESCRIPTION DRUGS Enhanced Efforts and Better Agency Coordination Needed to Address Illegal Importation Statement of Richard M. Stana, Direc...
Date Nov. 14, 2005	Report No. GAO-06-109	Title Food and Drug Administration: Decision Process to Deny Initial Application for Over-the-Counter Marketing of the Emergency Contraceptive Drug Plan B Was Unusual United States Government Accountability Office GAO November 2005 Report to Congressional Requesters FOOD AND DRUG ADMINISTRATION Decision Process to Deny Initial Application for Over-the-Counter Marketing of the Emergency Contraceptive Drug Plan B Was Unusual GAO-06-109 November 2005 FOOD AND DRUG ADMINISTRATION Highlights Highlights of GAO-06-109, a report to congressional requesters Accountabili...
Date Oct. 31, 2005	Report No. GAO-06-17R	Title Medicare: Comments on CMS Proposed 2006 Rates for Specified Covered Outpatient Drugs and Radiopharmaceuticals Used in Hospitals United States Government Accountability Office Washington, DC 20548 October 31, 2005 The Honorable Charles E. Grassley Chairman The Honorable Max Baucus Ranking Minority Member Committee on Finance United States Senate The Honorable Joe Barton Chairman The Honorable John D. Dingell Ranking Minority Member Committee on Energy and Commerce House of Representatives The Honorable William M. Thomas Cha...
Date Oct. 31, 2005	Report No. GAO-06-69R	Title Medicaid: States' Payments for Outpatient Prescription Drugs United States Government Accountability Office Washington, DC 20548 October 31, 2005 The Honorable Edward Whitfield Chairman Subcommittee on Oversight and Investigations Committee on Energy and Commerce House of Representatives Subject: Medicaid: States’ Payments for Outpatient Prescription Drugs Dear Mr. Chairman: Spending on outpatient prescription drug coverage for Medicaid beneficiaries has ...
Date Sept. 8, 2005	Report No. GAO-05-372	Title Prescription Drugs: Strategic Framework Would Promote Accountability and Enhance Efforts to Enforce the Prohibitions on Personal Importation United States Government Accountability Office GAO September 2005 Report to Congressional Requesters PRESCRIPTION DRUGS Strategic Framework Would Promote Accountability and Enhance Efforts to Enforce the Prohibitions on Personal Importation GAO-05-372 September 2005 PRESCRIPTION DRUGS Highlights Highlights of GAO-05-372, a report to congressional requesters Accountability Integrity Reliability Str...
Date Aug. 15, 2005	Report No. GAO-05-779	Title Prescription Drugs: Price Trends for Frequently Used Brand and Generic Drugs from 2000 through 2004 United States Government Accountability Office GAO August 2005 Report to Congressional Requesters PRESCRIPTION DRUGS Price Trends for Frequently Used Brand and Generic Drugs from 2000 through 2004 GAO-05-779 August 2005 PRESCRIPTION DRUGS Highlights Highlights of GAO-05-779, a report to congressional requesters Accountability Integrity Reliability Price Trends for Frequently Used Brand and Generic...

181 results

« ← Previous 1 2 3 4 Next → »

Weekly Updates

Caught Our Eye Rss

Social Media

DevBlog Rss

In the News

GAO Reports by subject "Pharmaceutical industry"

Search Results: